Sertraline for social anxiety disorder

Expert Review of Neurotherapeutics

Volumn 3, Issue 6, 2003, Pages 787-795

  Sokolenko, Marina ^a   Kutcher, Stan ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Antidepressants; Anxiety disorders; Selective serotonin reuptake inhibitors; Sertraline; Social anxiety disorder; Social phobia

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPRAZOLAM; AMFEBUTAMONE; BETA ADRENERGIC RECEPTOR; CARBAMAZEPINE; CHOLINERGIC RECEPTOR; CITALOPRAM; CLONAZEPAM; CLOZAPINE; DESIPRAMINE; DIAZEPAM; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; LITHIUM; METOPROLOL; NEFAZODONE; PAROXETINE; PHENYTOIN; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOLBUTAMIDE; UNINDEXED DRUG; VENLAFAXINE; WARFARIN; ZOLPIDEM;

AGITATION; APATHY; BLEEDING; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DYSPEPSIA; EJACULATION DISORDER; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INHIBITION KINETICS; INSOMNIA; NAUSEA; NEUROTOXICITY; PANCREATITIS; PHARMACODYNAMICS; PSYCHOMOTOR DISORDER; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; SWEATING; TREMOR; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

EID: 0344014165     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.3.6.787     Document Type: Review

References (87)

1. Greenberg PE, Sisitsky T, Kessler RC et al. The economic burden of anxiety disorders in the 1990. J. Clin. Psychiatry 60, 427-430 (1999).
2. Lepine JP. The Epidemiology of anxiety disorders: prevalence and societal costs. J. Clin. Psychiatry 63(Suppl. 14), 4-8 (2002).
3. Kessler RC, McGonagle KA, Zhao S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch. Gen. Psychiatry 51, 8-19 (1994). Classic article on the prevalence of anxiety disorders.
4. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. American Psychiatric Association, Washington DC, USA (1994).
5. World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organization, Geneva, Switzerland (1992).
6. Kessler RC, Stein MB, Berglund PA. Social phobia subtypes in the National Comorbidity Survey. Am. J. Psychiatry 155, 613-619 (1998).
7. Katzelnik DJ, Greist JH. Social anxiety disorder: an unrecognized problem in primary care. J. Clin. Psychiatry 62(Suppl. 11), 11-15 (2001).
8. Stein MB, Kean YM. Disability and quality of life in social phobia: epidemiologic findings. Am. J. Psychiatry 157(10), 1606-1613 (2000).
9. Katzelnick DJ, Kobak KA, DeLeire T et al. impact of generalized social anxiety disorder in managed case. Am. J. Psychiatry 158(12), 1999-2007 (2001).
10. Lydiard RB. social anxiety disorder: comorbidity and its implications. J. Clin. Psychiatry 62(Suppl. 1), 17-25 (2001).
11. Schneier FR, Johnson J, Hornig CD, Liebowitz MR, Weissman MM. Social phobia: comorbidity and morbidity in an epidemiological sample. Arch. Gen. Psychiatry 49, 282-288 (1992).
12. Kessler RC, Stang P, Wittchen H-U, Stein MB, Walters EE. Lifetime comorbidities between social phobia and mood disorders in the US National Comorbidity Survey. Psychol. Med. 29, 555-567 (1999).
13. Pini S, Cassano GB, Simonini E, Savino M, Russo A, Montgomery SA. Prevalence of anxiety disorders comorbidity in bipolar depression, unipolar depression and dysthymia. J. Affect. Disord. 42, 145-153 (1997).
14. Stein MB, Chavira DA. Subtypes of social phobia and comorbidity with depression and other anxiety disorders. J. Affect. Disord. 50, S11-S16 (1998).
15. Coupland NJ. Social phobia: etiology, neurobiology and treatment. J. Clin. Psychiatry 62(Suppl. 1), 25-35 (2001).
16. Bell CJ, Malizia AL, Nutt DJ. The neurobiology of social phobia. Eur. Neuropsychopharmacol. 8, 311-313 (1998).
17. Pollack MH. Comorbidity, neurobiology and pharmacotherapy of social anxiety disorder. J. Clin. Psychiatry 62(Suppl. 12), 24-30 (2001).
18. Schneier FR, Michael R, Liebowitz, Abi-Dargham A et al. Low dopamine D2 receptor binding potential in social phobia. Am. J. Psychiatry 157(3), 457-459 (2000).
19. Stein DJ, Westenberg HGM, Liebowitz MR. Social anxiety disorder and generalized anxiety disorder: serotonergic and dopaminergic neurocircuitry. J. Clin. Psychiatry 63(Suppl. 6), 12-19 (2002).
20. Mathew SJ, Coplan JD, Jack M. Gorman JM. Neurobiological mechanisms of social anxiety disorder. Am. J. Psychiatry 158(10), 1558-1567 (2001). Review.
21. Otto MW, Pollack MH, Gould RA, Worthington JJ 3rd, McArdle ET, Rosenbaum JF. A comparison of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. J. Anxiety Dis. 14, 345-358 (2000).
22. Liebowitz MR, Heimberg RG, Schneier FR et al. Cognitive-behavioral group therapy versus phenelzine in social phobia:long-term outcome. Depress. Anxiety 10, 89-98 (1999).
23. Radomsky A, Otto MW. Cognitive-behavioral therapy for the treatment of social anxiety disorder. Psychiatr. Clin. North Am. 24, 805-815 (2001).
24. Shear MK, Beidel DC. Psychotherapy in the overall management strategy for social anxiety disorder. J. Clin. Psychiatry 59(Suppl. 17), 39-46 (1998).
25. Otto MW. Cognitive-behavioral therapy for social anxiety disorder: model, methods and outcome. J. Clin. Psychiatry 60(Suppl. 9), 14-19 (1999).
26. Blomhoff S, Haug TT, Hellstrom K et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalized social phobia. Br. J. Psychiatry 179(7), 23-30 (2001).
27. Haug TT, Blomhoff S, Hellstrom K et al. Exposure therapy and sertraline in social phobia: 1 year follow-up of a randomised controlled trial. Br. J. Psychiatry 182(4), 312-318 (2003).
28. Schneier FR. Treatment of social phobia with antidepressants. J. Clin. Psychiatry 62(Suppl. 1), 43-49 (2001).
29. Jefferson JW. Benzodiazepines and anticonvulsants for social phobia. J. Clin. Psychiatry 62(Suppl. 1), 50-53 (2001).
30. Schatzberg AF. New indications for antidepressants. J. Clin. Psychiatry 61(Suppl. 11), 9-17 (2000).
31. Van Ameringen MA, Mancini C, Farvolden P, Oakman J. Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI. Expert Opin. Investig. Drugs. 9(10), 2215-2231 (2000).
32. Nardi AE. Antidepressants in social anxiety disorder. Arq. Neuropsiquiatr. 59(3A), 637-642 (2001).
33. Van Ameringen MA, Mancini C, Oakman JM, Farvolden P. Selective serotonin re-uptake inhibitors in the treatment of social phobia. The emerging gold standard. CNS Drugs 11(4), 307-315 (1999).
34. Richelson E. Pharmacology of antidepressants. Mayo Clin. Proc. 76, 511-527 (2001).
35. MacQueen G, Born L, Steiner M. The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev. 7(1), 1-24 (2001). Comprehensive review.
36. DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clin. Pharmacokinet. 41(15), 1247-1266 (2002). Review.
37. Preskorn S. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Int. Clin. Psychopharmacology 9(Suppl. 3), 13-19 (1994).
38. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin. Pharmacokinet. 31(6), 444-469 (1996).
39. Alderman J, Wolkow R, Chung M, Johnston HF. Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability and efficacy. J. Am. Acad. Child. Adolesc. Psychiatry 37(4), 386-394 (2001).
40. Axelson DA, Perel JM, Birmaher B et al. Sertraline pharmacokinetics and dynamics in adolescents. J. Am. Acad. Child. Adolesc. Psychiatry 41(9), 1037-1044 (2002).
41. Zoloft® (sertraline) product monograph. Pfizer, MI, USA
42. Lee DO, Lee CD. Serotonin syndrome in a child associated with erythromycin and sertraline. Pharmacotherapy 19(7), 894-896 (1999).
43. Markowitz JS, DeVaneCL. Rifampin-induced selective serotonin reuptake inhibitor withdrawal syndrome in a patient treated with sertraline. J. Clin. Psychopharmacol. 20, 109-110 (2000).
44. Pihlsgard M, Eliasson E. Significant reduction of sertraline plasma levels by carbamazepine and phenytoin. Eur. J. Clin. Pharmacol. 57(12), 915-916 (2002).
45. Hoehns JD, Fouts MM, Kelly MW, Tu KB. Sudden cardiac death with clozapine and sertraline combination. Ann. Pharmacother. 35(7-8), 862-866 (2001).
46. Liston HL, DeVane CL, Boulton DW, Risch SC, Markowitz JS, Goldman J. Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline and paroxetine in healthy volunteers. Comprehensive review. J. Clin. Psychopharmacol. 22(2), 169-173 (2002).
47. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr. Drug Metab. 3(1), 13-37 (2002). Comprehensive review.
48. Van Ameringen M, Mancini C, Streiner D. Sertraline in social phobia. J. Affect. Disord. 31(2), 141-145 (1994)
49. Munjack DJ, Flowers C, Eagan TV. Sertraline in social phobia. Anxiety 1(4), 196-198 (1994-95).
50. Czepowicz VD, Johnson MR, Lydiard RB et al. Sertraline in social phobia. J. Clin. Psychopharmacol. 15(5), 372-373, (1995)
51. Martins EA, Pigott TA, Bernstein SE et al. Sertraline in the treatment of patients with social phobia. Anxiety 1(6), 291-297 (1994-95).
52. Compton SN, Grant PJ, Chrisman AK, Gammon PJ, Brown VL, March JS. Sertraline in children and adolescents with social anxiety disorder: an open trial. J. Am. Acad. Child. Adolesc. Psychiatry 40(5), 564-571 (2001).
53. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mande JM, Serlin RC. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am. J. Psychiatry 152(9), 1368-1371 (1995). Double-blind controlled study.
54. Van Ameringen MA, Lane RM, Walker JR, Bowen RC et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry. 158(2), 275-281 (2001). Double-blind controlled study.
55. Liebowitz MR, DeMartinis N, Weihs K et al. Efficacy of sertraline in severe generalized anxiety disorder: results of a double-blind Placebo-controlled study. Personal communication with Pfizer, (Spring 2003).
56. Walker JR, Van Ameringen MA, Swinson R et al. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J. Clin. Psychopharmacol. 20(6), 636-644 (2000). Comprehensive review.
57. Blomhoff S, Haug TT, Hellstrom K et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalized social phobia. Br. J. Psychiatry 179(7), 23-30 (2001).
58. Goodnick PJ, Jerry J, Parra F. Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin. Pharmacother. 3(5), 479-498 (2002).
59. Wilens TE, Biederman J, March JS et al. Absence of cardiovascular adverse effects of sertraline in children and adolescents. J. Am. Acad. Child. Adolesc. Psychiatry 38(5), 573-577 (1999).
60. Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders-III. Tolerability, safety and economics. J. Psychopharmacol. 12(Suppl. 1), 43-49 (1998).
61. Murphy TK, Bengtson MA, Tan JY, Carbonell E, Levin GM. Selective serotonin reuptake inhibitors in the treatment of paediatric anxiety disorders: a review. Int. Clin. Psychopharmacol. 15(Suppl. 2), S47-S63 (2000).
62. Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am. J. Psychiatry 158(12), 2008-2014 (2001).
63. Findling RL, Reed MD, Blumer JL. Pharmacological treatment of depression in children and adolescents. Paediatr. Drugs 1(3), 161-182 (1999).
64. Cook EH, Wagner KD, March JS et al. Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J. Am. Acad. Child. Adolesc. Psychiatry 40(10), 1175-1181 (2001).
65. March JS, Biederman J, Wolkow R et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicentre randomized controlled trial JAMA 280(20), 1752-1756 (1998).
66. Nixon MK, Milin R, Simeon JG, Cloutier P, Spenst W. Sertraline effects in adolescent major depression and dysthymia: a 6 month open trial. J. Child. Adolesc. Psychopharmacol. 11(2), 131-142 (2001).
67. Fava M. Weight gain and antidepressants. J. Clin. Psychiatry 61 (Suppl. 11), 41-47 (2000).
68. Ferguson JM. The effects of antidepressants on sexual functioning in depressed patients: a review. J. Clin. Psychiatry 62(Suppl. 3), 22-34 (2001).
69. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J. Clin. Psychiatry 62(Suppl. 3), 10-21 (2001).
70. Fartoux-Heymann L, Hezode C, Zafrani ES, Dhumeaux D, Mallat A. Acute fatal hepatitis related to sertraline. J. Hepatol. 35(5), 683-684 (2001).
71. Spigset O, Hagg S, Bate A. A hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. Int. Clin. Psychopharm. 18 (3), 157-161 (2003).
72. Persky S, Reinus JF. Sertraline hepatotoxicity: A case report and review of the literature on selective serotonin reuptake inhibitor hepatotoxicity. Dig. Dc. 48 (5), 934-944 (2003).
73. Carvajal GP, Garcia D, Sanchez SA, Velasco MA, Rueda D, Lucena MI. Hepatotoxicity associated with the new antidepressants. J. Clin. Psychiatry 64(2), 135-137 (2002).
74. Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern. Med. 163(1), 59-64 (2003).
75. Bak S, Tsiropoulos I, Kjaersgaard JO et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke 33(6), 1465-1473 (2002).
76. Layton D, Clark DW, Pearce GL, Shakir SA. Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England. Eur. J. Clin. Pharmacol. 57(2), 167-176 (2001).
77. Lake MB, Birmaher B, Wassick S, Mathos K, Yelovich AK. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. J. Child. Adolesc. Psychopharmacol. 10(1), 35-38 (2000).
78. Klein-Schwartz W, Anderson B. Analysis of the sertraline only overdose. Am. J. Emerg. Med. 14, 456-458 (1996).
79. Kulin NA, Pastuszak A, Sage SR et al. Pregnancy outcome following maternal use of the new selective serotonin re-uptake inhibitors: a prospective controlled multicenter study. JAMA 279(8), 609-610 (1998).
80. Wilton LW, Pearch YL, Martin RM, Mackay FJ, Mann RD. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br. J. Obstet. Gynecol. 105, 882-889.
81. Stowe ZN, Hostetter AL, Owens MJ et al. The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. J. Clin. Psychiatry 64(1), 73-80 (2003).
82. Epperson N, Czarkowski KA, Ward-O'Brien D et al. Maternal sertraline treatment and serotonin transport in breastfeeding mother-infant pairs. Am. J. Psychiatry 158(10), 1631-1637 (2001).
83. Hendrick V, Fukuchi A, Altshuler L, Widawski M, Wertheimer A, Brunhuber MV. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br. J. Psychiatry 179, 163-166 (2001).
84. Kristensen JH, Ilett KF, Dusci LJ et al. Distribution and excretion of sertraline and N-desmethylsertraline in human milk. Br. J. Clin. Pharmacol. 45(5), 453-457 (1998).
85. Wisner KL, Perel JM, Blumer J. Serum sertraline and N-desmethylsertraline levels in breast-feeding mother-infant pairs. Am. J. Psychiatry 155(5), 690-692 (1998).
86. Gallenger JC, Davidson JR, Lecruiber Y et al. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J. Clin. Psychiatry 59(Suppl. 17), 54-80 (1998).
87. Anxiety Review Panel. Evans M, Bradwejn J, Dunn L (Eds). Ontario Guidelines for the Management of Anxiety Disorders in Primary Care. Queen's Printer of Ontario, Toronto, Canada (2002).